In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4272-4279

  Pramudji, Christina ^a   Shimura, Satoru ^a   Ebara, Shin ^a   Yang, Guang ^a   Wang, Jianxiang ^a   Ren, Chengzhen ^a   Yuan, Yunfei ^a   Tahir, Salahaldin A ^a   Timme, Terry L ^a,b   Thompson, Timothy C ^a,a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADCAV 1TK; ADCMVTK; ADRSVTK; CAVEOLIN 1; HSV TK; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; ROUS SARCOMA ONCOVIRUS; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CAVEOLIN 1; CAVEOLINS; CELL SURVIVAL; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0035675839     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cancer statistics, 2001
2. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
3. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice
4. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
5. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer
6. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate
7. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: Pathogenetic and clinical implications
8. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
9. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
10. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors
11. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV tk gene involves an immune component
12. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats
13. In situ gene therapy for prostate cancer: Immunomodulatory approaches
14. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
15. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines
16. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer
17. In situ gene therapy for adenocarcinoma of the prostate: A Phase I clinical trial
18. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
19. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer
20. Metastasis-related genes in prostate cancer: The role of caveolin-1
21. Elevated expression of caveolin is associated with prostate and breast cancer
22. Caveolin, a protein component of caveolae membrane coats
23. Caveolae and caveolins
24. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker
25. Elevated caveolin-1 levels in African-American versus white-American prostate cancer
26. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells
27. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis
28. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells
29. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer
30. Up-regulation of caveolae and caveolar constituents in multidrug- resistant cancer cells
31. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells
32. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
33. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer
34. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression
35. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer
36. Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1)
37. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53
38. Manipulation of adenoviral vectors
39. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
40. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
41. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
42. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
43. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter
44. The dual impact of Coxsackie and adenovirus receptor expression on human prostate cancer gene therapy